[1]CASTLEMAN B,IVERSON L,MENENDEZ V P.Localized mediastinal lymphnode hyperplasia resembling thymoma[J].Cancer,1956,9(4):822-830.DOI:10.1002/1097-0142(195607/08)9:4<;822::aid-cncr2820090430>;3.0.co;2-4.
[2]DISPENZIERI A,ARMITAGE J O,LOE M J,et al.The clinical spectrum of Castleman's disease[J].Am J Hematol,2012,87(11):997-1002.DOI:10.1002/ajh.23291.
[3]丁思睿赟,郭鹏翔.噬血细胞综合征的病因及诊断进展[J].中外医疗,2015,34(10):197-198.DOI:10.16662/j.cnki.1674-0742.2015.10.032.
DING S R Y,GUO P X.Progress in etiology and diagnosis and treatment of hemophagocytic syndrome[J].China Foreign Medical Treatment,2015,34(10):197-198.DOI:10.16662/j.cnki.1674-0742.2015.10.032.
[4]LEGER-RAVET M B,PEUCHMAUR M,DEVERGNE O,et al.Interleukin-6 gene expression in Castleman[J].Blood,1991,78(11):2923-2930.
[5]FAJGENBAUM D C,VAN RHEE F,NABEL C S.HHV-8-negative,idiopathic multicentric Castleman disease:novel insights into biology,pathogenesis,and therapy[J].Blood,2014,123(19):2924-2933.DOI:10.1182/blood-2013-12-545087.
[6]VAN RHEE F,WONG R S,MUNSHI N,et al.Siltuximab for multicentric Castleman's disease:a randomised,double-blind,placebo-controlled trial[J].Lancet Oncol,2014,15(9):966-974.DOI:10.1016/S1470-2045(14)70319-5.
[7]刘勇,杨海玉.Castleman病的研究进展[J].临床与实验病理学杂志,2015,31(1):70-72.DOI:10.13315/j.cnki.cjcep.2015.01.018.http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=lcysyblxzz2015010023.
[8]MALINOWSKA I,MACHACZKA M,POPKO K,et al.Hemophagocytic syndrome in children and adults[J].Arch Immunol Ther Exp(Warsz),2014,62(5):385-394.DOI:10.1007/s00005-014-0274-1.
[9]CHEN Y Y,WANG Z J,LUO Z B,et al.Comparison of Th1/Th2 cytokine profiles between primary and secondary haemophagocytic lymphohistiocytosis[J].Ital J Pediatr,2016,42(1):50.DOI:10.1186/s13052-016-0262-7.
[10]ROSSOTTI R,MOIOLI C,SCHIANTARELLI C,et al.FDG-PET imaging in the diagnosis of HIV-associated multicentric Castleman disease:something is still missing[J].Top Antivir Med,2012,20(3):116-118.
[11]寿娟,龙艳丽,粟凤,等.Castleman病继发霍奇金淋巴瘤临床病理分析并文献复习[J].华中科技大学学报(医学版),2017,46(5):612-614.DOI:10.3870/j.issn.1672-0741.2017.05.024.http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=tjykdxxb201705024.
[12]HENTER J I,HORNE A,ARICó M,et al.HLH-2004:diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J].Pediatr Blood Cancer,2007,48(2):124-131.DOI:10.1002/pbc.21039.
[13]张路,李剑.多中心型Castleman病的治疗进展[J].国际药学研究杂志,2017,44(2):162-166.DOI:10.13220/j.cnki.jipr.2017.02.014.
ZHANG L,LI J.Treatment of multicentric Castleman's disease:research advances[J].Journal of International Pharmaceutical Research,2017,44(2):162-166.DOI:10.13220/j.cnki.jipr.2017.02.014.
[14]CASQUERO A,BARROSO A,FERNáNDEZ GUERRERO M L,et al.Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease[J].Ann Hematol,2006,85(3):185-187.DOI:10.1007/s00277-005-0038-4.
[15]NISHIMOTO N,KANAKURA Y,AOZASA K,et al.Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease[J].Blood,2005,106(8):2627-2632.DOI:10.1182/blood-2004-12-4602.
[16]GALEOTTI C,BOUCHERON A,GUILLAUME S,et al.Sustained remission of multicentric Castleman disease in children treated with tocilizumab,an anti-interleukin-6 receptor antibody[J].Mol Cancer Ther,2012,11(8):1623-1626.DOI:10.1158/1535-7163.MCT-11-0972.